The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Incidence of thyroid dysfunction in renal cell carcinoma (RCC) patients treated with pazopanib in prospective clinical trials.
P. Wolter
No relevant relationships to disclose
L. McCann
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
C. N. Sternberg
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer
T. E. Hutson
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Pfizer; Wyeth
Honoraria - Bayer; GlaxoSmithKline; Pfizer; Wyeth
Research Funding - Bayer; GlaxoSmithKline; Pfizer; Wyeth
F. Mehmud
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
L. N. Pandite
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
P. Schoffski
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline